Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Disaggregation of Income Statement Expenses

This following table presents segment operation results for the year ended December 31, 2024, 2023 and 2022:

	Year Ended December 31,
	2024		2023		2022
Operating expenses:
Research and development - external costs (1)	$	349,510	$	261,984	$	132,418
Research and development - internal costs (2)	127,134		70,357		37,033
Acquired manufacturing rights (Note 7)	—		75,000		22,995
General and administrative	92,902		60,700		39,810
Total operating expenses	$	569,546	$	468,041	$	232,256
Total other income, net	$	105,619	$	65,775	$	8,771
Net loss	$	463,927	$	402,266	$	223,485

____________________________________________________________

(1)Research and development - external costs consist primarily of product and clinical development expenses, research and development consumables, lab supplies and equipment, facility, depreciation, professional and consulting services attributed to the research and development departments.

(2)Research and development - internal costs consist of internal employee costs including stock-based compensation expenses.